#pharma sector

New Delhi: White-collar hiring in India witnessed a healthy start to FY 2025-26, registering a 9 per cent year-on-year growth in April, according to a report on Thursday. The report by job portal Naukri showed the growth was driven by several sectors, with pharma (+14 per cent), real estate (+11 per cent), GCCs (+10 per cent) and oil and gas (+9 per cent) emerging as primary contributors to the…

Pharma Sector Shows Resilience Amid Market Fluctuations. #pharma #pharmastock #pharmastockmarket

Pharma Sector Shows Resilience Amid Market Fluctuations: In the ever-evolving panorama of the pharmaceutical enterprise, recent developments have indicated a mixture of demanding situations and possibilities. Despite a widespread downturn in pharma stocks, savvy traders are locating bargains that promise extensive returns. Pharma Sector Shows Resilience Amid Market Fluctuations Bargain Stocks…

Varanasi, February 4: Uttar Pradesh Chief Minister Yogi Adityanath on Saturday said that Uttar Pradesh has immense potential in the pharmaceutical sector and is set to emerge as a major pharmaceutical centre within the country in the times to come as it provides adequate manpower, better road connectivity, adequate land bank and safe environment and sector-wise policies. Chief Minister Yogi…

Who Are The Leaders In Pharmaceutical Industry?

Multinational drug major Boehringer Ingelheim (BI) has obtained ad-interim injunctions against four domestic pharmaceutical companies -- Eris Lifesciences, Emcure Pharma, Optimus Pharma and MSN Laboratories. These companies had launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name Trajenta.

The company also secured injunctions against Dr Reddy's Laboratories (DRL) and MSN Laboratories earlier for its diabetic drug Empagliflozin marketed as Jardiance in India.

Also, the company had secured an ad-interim injunction against Macleods Pharma for its Linagliptin drug, which was eventually made absolute.

The global active pharmaceutical ingredients market size is expected to reach USD 312.56 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.6% from 2021 to 2028. The market is driven by the growth of the biopharmaceutical sector, advancements in active pharmaceutical ingredient (API) manufacturing, and an increase in the geriatric population.

The growth of the captive API segment is propelled by companies investing in solving challenges and developing new chemical ways for the production of APIs in house. This aids in reducing costs and the risk of contamination. Artificial intelligence and protein synthesis are expected to facilitate faster development with greater control over the process.

The rising prevalence of chronic and lifestyle-based conditions, such as cardiovascular diseases, is accelerating the demand for API. For instance, as per U.S. Pharmacist in 2020, 47% of adults have at least one risk factor that supports cardiovascular disease development. Cardiovascular diseases are one of the global, critical public health burdens driving extensive R&D for APIs in the field.

The generic API segment is gaining share in the market owing to its cost effectiveness, which helps in catering to the needs of the rising number of patients in developing regions with a low-income population. According to the Association for Accessible Medicines (AAM), in 2017, there was a considerable rise in manufacturing units in Asia, Australia, and EU5. There has also been an increase in the market share of generic drugs.

Developing nations like India are receiving an increased preference in the market over dominant API market countries, like China, owing to geopolitical situations. Furthermore, other factors favoring India include quality raw materials and products, large workforce, vast distribution network, and government subsidies under schemes like “Make in India”.

For addressing unmet medical needs, companies are collaborating to develop novel treatments. This allows firms to use their resources to aid in the development of products and enhance the supply chain. In August 2019, OmniChem Private Limited was acquired by Ajinomoto Bio-Pharma Services (earlier they were in a joint venture since 2011 for the manufacturing of APIs). The acquisition was completed in June 2020.

Indian pharma industry captains feel that the current production linked incentive (PLI) scheme for the pharmaceutical industry can be expanded to link it to research, and more specifically for research in biologics and biosimilars.

Speaking at BioAsia 2022, Kiran Mazumdar Shaw, executive chairperson, Biocon Group, said that there needs to be a different PLI scheme that needs to focus on the emerging opportunities for Indian pharma. “As a nation we need to start moving towards large molecules of biologics. There is a huge growing interest in combination immuno-therapies. Can we leap-frog? The PLI scheme was far too skewed far too much towards generic drugs. There should have been a much greater allocation for biologics, biosimilars, cell and gene therapies etc, which did not happen,” Shaw explained.

In fact she cited the example of Biocon to say, “We could not be eligible for category A companies because we did not have that many ANDAs. So, we got a very small amount.”

The Rs 15,000 crore PLI scheme announced by the Centre has three categories of companies – category A (FY20 global manufacturing revenue of pharma goods more than equal to Rs 5000 crore), category B (between Rs 500 crore to Rs 5000 crore) and category C (revenue less than Rs 500 crore). The quantum of incentives vary for the three groups – Rs 11,000 crore (Group A), Rs 2250 crore (Group B) and Rs 1750 crore (Group C).